CSP10

PREVALENCE AND RISK FACTORS OF POTENTIALLY INAPPROPRIATE

MEDICATION USE IN COMMUNITY-RESIDING OLDER ADULTS: PRELIMINARY
RESULTS FROM THE EUROAGEISM H2020 PROJECT

BRKIĆ, J., 1 REISSIGOVÁ, J., 2 FIALOVÁ, D.,1,3 AND ESR 7 EUROAGEISM H2020 RESEARCH TEAM
FROM 8 PARTICIPATING COUNTRIES

1
Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
2
Department of Statistical Modelling, Institute of Computer Science, Czech Academy of Sciences, Czech Republic
3
Department of Geriatrics and Gerontology, 1st Faculty of Medicine, Charles University, Czech Republic

e-mail: jovanabrkic37@gmail.com

The use of potentially inappropriate medications (PIMs) in older adults is a growing public health concern around
the globe1,2,3. This study was set out to assess the prevalence and risk factors of PIM use in community-dwelling
older adults in several European countries. A cross-sectional multicentric study was conducted in 8 countries, but
we present preliminary results from 5 countries: Croatia, the Czech Republic, Serbia, Spain and Turkey. Data
were collected using a structured protocol based on comprehensive geriatric assessment containing more than
300 socio-demographic and clinical characteristics. We assessed the prevalence of PIM using both EU(7)-PIM
list4 and American Geriatrics Society 2019 Beers Criteria5. We determined the factors associated with PIM use
by stepwise multiple logistic regression. We included 2011 participants, most of whom were women, 59.1 %.
The total prevalence of PIM use was 61.4 %, ranging from 37.1 % in the Czech Republic to 74.4 % in Croatia.
The factors significantly associated with PIM use (p<0.05) were: being female 1.30 (1.05-1.61); polypharmacy
(5+ medications) 6.12 (4.94-7.58); being diagnosed with depression 2.37 (1.56-3.61), and residing in the Czech
Republic 0.30 (0.21-0.41) and Turkey 0.45 (0.33-0.63) (reference country: Croatia). These preliminary findings
confirm that PIM use in community-dwelling older adults is highly prevalent, and interventions to reduce it
should primarily focus on risky cohorts of older adults, such as females, patients using polypharmacy and
suffering from depression.
The study was supported by projects: EuroAgeism Horizon 2020 MSCF-ITN-764632, Inomed
NO.CZ.02.1.01/0.0/0.0/18_069/0010046, Progress Q42-Faculty of Pharmacy, Charles University,
START/MED/093 CZ.02.2.69/0.0/0.0/19_073/0016935, SVV260 551 and ICARE4OLD H2020 -965341

References
1. MORIN, L., LAROCHE, M., TEXIER, G., et al.: J. Am. Med. Dir. Assoc., 17, 2016, 862.E1–862.E9.
2. TOMMELEIN, E., MEHUYS, E., PETROVIĆ, M., et al.: Eur. J. Clin. Pharmacol., 71, 2015, 1415‒1427.
3. FIALOVÁ, D., TOPINKOVÁ, E., GAMBASSI, G., et al.: Jama, 293, 2005, 1348‒1358.

11
CSP10

4. 2019 AMERICAN GERIATRICS SOCIETY BEERS CRITERIA® UPDATE EXPERT PANEL: J. Am.
Geriatr. Soc., 67, 2019, 674–94.
5. RENOM-GUITERAS, A., MEYER, G., THÜRMANN, P.A.: Eur. J. Clin. Pharmacol., 71, 2015, 861‒75.

12